NC Registry

11/17/2023

There is a clinical trial combining a BET inhibitor, ZEN003694, with CDK inhibitor, abemaciclib, for adult and pediatric patients (Age >= 12) with NUT Carcinoma. Additional information about this trial can be found at the following link:
https://clinicaltrials.gov/study/NCT05372640

11/17/2023

There is a clinical trial utilizing a dual BET and CBP/p300 inhibitor in adult patients with targeted advanced solid tumors (including NUT Carcinoma). Additional information about this trial can be found at the following link:
https://clinicaltrials.gov/study/NCT05488548?term=NCT05488548&rank=1

07/04/2022

There is a clinical trial combining a BET inhibitor, ZEN003694, with chemotherapy treatment (etoposide and cisplatin) for adult and pediatric patients (12-17 Years) with NUT Carcinoma. Additional information about this trial can be found at the following link:

https://clinicaltrials.gov/ct2/show/NCT05019716?term=NCT05019716&draw=2&rank=1

12/22/2020

Two new testing sites are open for the clinical trial sponsored by Boehringer Ingelheim. US locations include:
Dana-Farber Cancer Institute in Boston, MA
Memorial Sloan-Kettering Cancer Center in New York, NY
Cleveland Clinic in Cleveland, OH
The University of Texas MD Anderson Cancer Center in Houston, TX

Click the link for more information:

BI 894999 First in Human Dose Finding Study in Advanced Malignancies - Full Text View.

05/04/2019

A clinical trial sponsored by Boehringer Ingelheim is currently enrolling NMC patients!!! Enrollment is open in the US at the MD Anderson Cancer Center in Houston, TX and DFCI in Boston, MA.

Please see the link below for more information:
https://clinicaltrials.gov/ct2/show/NCT02516553?cond=BI+894999

02/12/2019

The New Jersey Assembly passed a joint resolution early this year designating January as NUT Carcinoma Awareness Month in the state of New Jersey!!

Read the article below for more information:

Benjamin Landel fought against a rare form of cancer for 9 months. The state Assembly Thursday passed a resolution in his honor.

01/30/2019

A new clinical trial sponsored by Boehringer Ingelheim is currently enrolling NMC patients!!! Enrollment will open in the US at the MD Anderson Cancer Center in Houston, TX followed by DFCI in Boston, MA during the first quarter of 2019.

Please see the link below for more information:

BI 894999 First in Human Dose Finding Study in Advanced Malignancies - Full Text View.

10/21/2017

Our research team receives financial support from the Closing the AYA Gap Fund, Alex’s Lemonade Stand Foundation, and the National Insititute of Health NCI grant (5RO1CA124633).

We also welcome donations to contribute to NMC cancer research and care at Dana-Farber Cancer Institute and Brigham and Women's Hospital. Please visit our Giving Page for more information: